면역치료 | 더블 타겟 CD19 CD22에 관한 논문
페이지 정보
작성자 HK HIS 작성일20-03-31 11:18 조회4,776회 댓글0건관련링크
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438143/
본문
Delayed remission following sequential infusion of humanized CD19- and CD22-modified CAR-T cells in a patient with relapsed/refractory acute lymphoblastic leukemia and prior exposure to murine-derived CD19-directed CAR-T cells
Background
CD19-modified CAR-T cells greatly influence responses in patients with relapsed/refractory acute lymphoblastic leukemia (ALL). However, recurrence remains a challenge, and reinfusion of CAR-T cells is not always effective. Sequential infusion of humanized CD19-modified and CD22-modified CAR-T cells may overcome this issue and induce remission.
Methods
We examined treatment with sequential infusion of humanized CD19-modified and CD22-modified CAR-T cells in a patient with relapsed ALL previously exposed to murine-derived anti-CD19 CAR-T cells.
